Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Comparison of renal clearance of [18F]AlF-RESCA-HER2-BCH and [18F]AlF-NOTA-HER2-BCH in mice and breast cancer patients

Published:2023-04-24 Issue:9 Volume:50 Page:2775-2786
ISSN:1619-7070
Container-title:European Journal of Nuclear Medicine and Molecular Imaging
language:en
Short-container-title:Eur J Nucl Med Mol Imaging

Author:

Liu Jiayue,Guo Xiaoyi,Wen Li,Wang Lixin,Liu Futao,Song Guohong,Zhu Hua,Zhou Nina,Yang Zhi^ORCID

Funder

National Natural Science Foundation of China

Capital’s Funds for Health Improvement and Research

Beijing Hospitals Authority Deng feng Project

The Pilot Project (4 th Round) to Reform Public Development of Beijing Municipal Medical Research Institute

Science Foundation of Peking University Cancer Hospital

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine,Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00259-023-06232-1.pdf

Reference42 articles.

1. Roskoski R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.

2. Meric-Bernstam F, Johnson AM, Dumbrava EEI, Raghav K, Balaji K, Bhatt M, et al. Advances in HER2-targeted therapy: novel agents and opportunities beyond breast and gastric cancer. Clin Cancer Res. 2019;25:2033–41.

3. Oh D-Y, Bang Y-J. HER2-targeted therapies — a role beyond breast cancer. Nat Rev Clin Oncol. 2020;17:33–48.

4. Zhu Y, Zhu X, Wei X, Tang C, Zhang W. HER2-targeted therapies in gastric cancer. Biochim Biophys Acta Rev Cancer. 2021;1876: 188549.

5. Fabi A, Di Benedetto A, Metro G, Perracchio L, Nisticò C, Di Filippo F, et al. HER2 protein and gene variation between primary and metastatic breast cancer: significance and impact on patient care. Clin Cancer Res. 2011;17:2055–64.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cyclohexanediamine Triazole (CHDT) Functionalization Enables Labeling of Target Molecules with Al¹⁸F/⁶⁸Ga/¹¹¹In;Bioconjugate Chemistry;2024-08-26

2. Evaluation of a novel 177Lu-labelled therapeutic Affibody molecule with a deimmunized ABD domain and improved biodistribution profile;European Journal of Nuclear Medicine and Molecular Imaging;2024-07-15

3. Comparison of an Affibody-based Molecular Probe and ¹⁸F-FDG for Detecting HER2-Positive Breast Cancer at PET/CT;Radiology;2024-06-01

4. Affibody PET Imaging of HER2-Expressing Cancers as a Key to Guide HER2-Targeted Therapy;Biomedicines;2024-05-14

5. Clinical Implementation of Total-Body PET in China;Journal of Nuclear Medicine;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3